Synthesis and structure-activity relationships of 3,7-dimethyl-1- propargylxanthine derivatives, A(2A)-selective adenosine receptor antagonists

Journal of Medicinal Chemistry

Volumn 40, Issue 26, 1997, Pages 4396-4405

  Müller, Christa E ^a,b   Geis, Uli ^a   Hipp, Jo ^a   Schobert, Ulrike ^a   Frobenius, Wolfram ^a   Pawłowski, Maciej ^a,c   Suzuki, Fumio ^b   Sandoval Ramírez, Jesús ^a,d  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

^c JAGIELLONIAN UNIVERSITY   (Poland)

^d BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

3 PROPARGYL 5,6 DIAMINOURACIL; 3,7 DIMETHYL 1 PROPARGYLXANTHINE; 8 (3 CHLOROSTYRYL)CAFFEINE; 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE; ADENOSINE A2 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; LIGAND BINDING; NONHUMAN; RAT; RECEPTOR AFFINITY; RECEPTOR BLOCKING; STRUCTURE ACTIVITY RELATION;

ADENOSINE; ANIMALS; BINDING, COMPETITIVE; BRAIN; CAFFEINE; MOLECULAR STRUCTURE; PHENETHYLAMINES; PROTEIN BINDING; RATS; RECEPTORS, PURINERGIC P1; STRUCTURE-ACTIVITY RELATIONSHIP; THEOBROMINE; XANTHINES;

EID: 0031463493     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970515+     Document Type: Article

References (57)

1. (a) Müller, C. E.; Stein, B. Adenosine receptor antagonists: structures and potential therapeutic applications. Curr. Pharm. Design 1996, 2, 501-530.
2. 1-Adenosine receptor antagonists. Exp. Opin. Ther. Pat. 1997, 7, 419-440.
3. Müller, C. E.; Scior, T. Adenosine receptors and their modulators. Pharm. Acta Helv. 1993, 68, 77-111.
4. Collis, M. G.; Hourani, S. M. O. Adenosine receptor subtypes. Trends Pharmacol. Sci. 1993, 14, 360-366.
5. Fredholm, B. B.; Abbracchio, M. P.; Burnstock, G.; Daly, J. W.; Harden, T. K.; Jacobson, K. A.; Leff, P.; Williams, M. VI. Nomenclature and Classification of Purinoceptors. Pharmacol. Rev. 1994, 46, 143-156.
6. Daly, J. W. Analogues of caffeine and theophylline: activity as antagonists at adenosine receptors. In Role of adenosine and adenine nucleotides in the biological system; Imai, S., Nakazawa, M., Eds.; Elsevier: Amsterdam, 1991; pp 119-129.
7. 6,9-Disubstituted adenines: Potent, selective antagonists at the A1 adenosine receptor. J. Med. Chem. 1991, 34, 2877-2882.
8. 6-(5′-endohydroxy-endonorbomyl)-9-methyladenine (WRC-0571), a highly potent and selective, non-xanthine antagonist of A1 adenosine receptors. J. Pharmacol. Exp. Ther. 1996, 276, 490-499.
9. (a) Müller, C. E.; Hide, I.; Daly, J. W.; Rothenhäusler, K.; Eger, K. 7-Deaza-2-phenyladenines: Structure-activity relationships of potent A1 selective adenosine receptor antagonists. J. Med. Chem. 1990, 33, 2822-2828.
10. (b) Müller, C. E.; Geis, U.; Grahner, B.; Lanzner, B.; Eger, K. Chiral pyrrolo[2,3-d]pyrimidine and pyrimido[4,5-b]indole derivatives: structure-activity relationships of potent, highly stereoselective A1-adenosine receptor antagonists. J. Med. Chem. 1996, 39, 2482-2491.
11. (a) Poulsen, S.-A.; Quinn, R. J. Pyrazolo[3,4-d]pyrimidines: C4, C6 substitution leads to adenosine A1 receptor selectivity. Bioorg. Med. Chem. Lett. 1996, 6, 357-360.
12. (b) Peet, N. P.; Lentz, N. L.; Sunder, S.; Dudley, M. W.; Ogden, A. M. L. Conformationally restrained, chiral (phenylisopropyl)amino-substituted pyrazolo[3,4-d]pyrimidines and purines with selectivity for adenosine A1 and A2 receptors. J. Med. Chem. 1992, 35, 3263-3269.
13. (a) Sarges, R.; Howard, H. R.; Browne, R. G.; Lebel, L. A.; Seymour, P. A.; Koe, B. K. 4-Amino[1,2,4)triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants. J. Med. Chem. 1990, 33, 2240-2254.
14. 2A adenosine binding activity. Eur. J. Med. Chem. 1995, 30, 133-139.
15. 2A adenosine receptor antagonists. Curr. Med. Chem. 1995, 2, 707-722.
16. (a) Mally, J.; Stone, T. W. The effect of theophylline on parkinsonian symptoms. J. Pharm. Pharmacol. 1994, 46, 515-517.
17. 2A receptor antagonist with anticataleptic activity. Eur. J. Pharmacol. 1994, 256, 263-268.
18. Daly, J. W.; Padgett, W. L.; Shamim, M. T. Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J. Med. Chem. 1996, 29, 1305-1308.
19. Seale, T. W.; Abla, K. A.; Shamim, M. T.; Carney, J. M.; Daly, J. W. 3,7-Dimethyl-1-propargylxanthine: a potent and selective in vivo antagonist of adenosine analogues. Life Sci. 1988, 43, 1671-1684.
20. Shamim, M. T.; Ukena, D.; Padgett, W.; Daly, J. W. Effects of 8-phenyl and 8-cycloalkyl substituents on activity of mono-, di-, and trisubstituted alkylxanthines with substituion at the 1-, 3-, and 7-positions. J. Med. Chem. 1989, 32, 1231-1237.
21. Shimada, J.; Suzuki, F.; Nonaka, H.; Ishii, A.; Ichikawa, S. (E)-1,3-Dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists. J. Med. Chem. 1992, 35, 2342-2345.
22. Jacobson, K. A.; Gallo-Rodriguez, C.; Melman, N.; Fischer, B.; Maillard, M.; van Bergen, A.; van Galen, P. J. M.; Karton, Y. Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine receptor antagonists. J. Med. Chem. 1993, 36, 1333-1342.
23. (a) Francis, J. E.; Cash, W. D.; Psychoyos, S.; Ghai, G.; Wenk, P.; Friedmann, R. C.; Atkins, C.; Warren, V.; Furness, P.; Hyun, J. L.; Stone, G. A.; Desai, M.; Williams, M. Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists. J. Med. Chem. 1988, 31, 1014-1020.
24. 2A adenosine antagonists. J. Med. Chem. 1996, 39, 1164-1171.
25. (c) Gatta, F.; Del Giudice, M. R.; Borioni, A.; Borea, P. A.; Dionisotti, S.; Ongini, E. Synthesis of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidines, pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines and 1,2,4-triazolo[5,1-i]purines: new potent A2 receptor antagonists. Eur. J. Med. Chem. 1993, 28, 569-576.
26. 2A adenosine receptor antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 2539-2544.
27. 2A selective adenosine receptor antagonist. Br. J. Pharmacol. 1995, 115, 1096-1102.
28. (a) Bruns, R. F. Structure-activity relationships for adenosine antagonists. In Purines in cellular signaling: targets for new drugs; Jacobson, K. A., Daly, J. W., Manganiello, V., Eds.; Springer: New York, 1990.
29. (b) Colotta, V.; Cecchi, L.; Catarzi, D.; Melani, F.; Filacchioni, G.; Martini, C.; Tacchi, P.; Lucacchini, A. 1-(3-Aminophenyl)-3-methyl[1]benzopyrano[2,3-c]pyrazolo-4-one: a new selective A2 adenosine receptor antagonist. Pharm. Pharmacol. Lett. 1992, 2, 74-76.
30. 2A adenosine binding activities of some 1-aryl-1,4-dihydro-3-methyl-[1]benzopyrano[2,3-c]pyrazol-4-ones, 1-aryl-4,9-dihydro-3-methyl-1H-pyrazolo[3,4-6]quinolin-4-ones, and 1-aryl-1H-imidazo[4,5-b]quinoxalines. J. Med. Chem. 1995, 38, 1330-1336.
31. Kramer, G. L.; Garst, J. E.; Mitchel, S. S.; Wells, J. N. Selective inhibition of cyclic nucleotide phosphodiesterases by analogues of 1-methyl-3-isobutylxanthine. Biochemistry 1977, 16, 3316-3321.
32. Papesch, V.; Schroeder, E. F. Synthesis of 1-mono- and 1,3-disubstituted 6-aminouracils. Diuretic activity. J. Org. Chem. 1951, 1879-1890.
33. Müller, C. E.; Shi, D.; Manning, M., Jr.; Daly, J. W. Synthesis of paraxanthine analogues (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors J. Med. Chem. 1993, 36, 3341-3349.
34. Müller, C. E. Formation of oxazolo[3,2-a]purinones from propynyluracils. J. Org. Chem. 1994, 59, 1928-1929.
35. Müller, C. E. General synthesis and properties of 1-monosubstituted xanthines. Synthesis 1993, 125-128.
36. Müller, C. E.; Sandoval-Ramírez, J. A new versatile synthesis of xanthines with variable substituents in the 1-, 3-, 7-, and 8-positions. Synthesis 1995, 1295-1299.
37. Traube, W.; Nithack, W. Über die Einwirkung von Aldehyden auf Orthodiamine der Pyrimidinreihe. (On the reaction of aldehydes with orthodiamine derivatives of pyrimidines). Chem. Ber. 1906, 39, 227-235.
38. Senga, K.; Shimizu, K.; Nishigaki, S. Oxidative cyclization of 6-amino-5-benzylidene-amino-1,3-dimethyluracils with thionyl chloride. A convenient synthesis of 8-substituted theophyllines. Chem. Pharm. Bull. 1977, 25, 495-497.
39. Rybár, A.; Hesek, D.; Szemes, F.; Alföldi, J.; Tegza, M. 3,7-Dialkyl-8-alkyl- or aryl-3,7-dihydropurine-2,6-diones. Collect. Czech. Chem. Commun. 1990, 55, 2257-2269.
40. 3H]CGS21680, a selective A2 adenosine receptor agonist directily labels A2 receptors in rat brain. J. Pharmacol. Exp. Ther. 1989, 251, 888-893.
41. Daly, J. W.; Hide, I.; Müller, C. E.; Shamim, M. Caffeine analogues: structure-activity relationships at adenosine receptors. Pharmacology 1991, 42, 309-321.
42. 2-adenosine receptor antagonists. J. Med. Chem. 1994, 37, 1526-1534.
43. 2A adenosine receptor antagonists. Eur. J. Med. Chem. 1996, 31, 59.-63.
44. Philip, J.; Szulczewski, D. H. Photo-induced isomerization of 8-(3,4,5-trimethoxystyryl)caffeine as possible route of drug decomposition. J. Pharm. Sci. 1973, 62, 1885-1887.
45. Nonaka, Y.; Shimada, J.; Nonaka, H.; Koike, N.; Aoki, N.; Kobayashi, H.; Kase, H.; Yamaguchi, K.; Suzuki, F. Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J. Med. Chem. 1993, 36, 3731-3733.
46. Kim, H. O.; Ji, X.-d.; Melman, N.; Olah, M. E.; Stiles, G. L.; Jacobson, K. A. Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors. J. Med. Chem. 1994, 37, 3373-3382.
47. Fiebich, B. L.; Biber, K.; Gyufko, K,; Berger, M.; Bauer, J.; van Calker, D. Adenosine A2b receptors mediate an increase in interleukin (IL)-6 mRNA and IL-6 protein synthesis in human astroglioma cells. J. Neurochem. 1996, 66, 1426-1431.
48. Nonaka, H.; Ichimura, M.; Takeda, M.; Nonaka, Y.; Shimada, J.; Suzuki, F.; Yamaguchi, K,; Kase, H. KF17837 ((E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine), a potent and selective adenosine A2 receptor antagonist. Eur. J. Pharmacol. Mol. Pharm. Sect. 1994, 267, 335-341.
49. Van Galen, P. J. M.; van Bergen, A. H.; Gallo-Rodriguez, C.; Melman, N.; Olah, M. E.; IJzerman, A. P.; Stiles, G. L.; Jacobson, K. A. A binding site model and structure-activity relationships for the rat A3 adenosine receptor. Mol. Pharmacol. 1994, 45, 1101-1111.
50. Ali, H.; Müller, C. E.; Daly, J. W.; Beaven, M. A. Methylxanthines block antigen-induced responses in RBL-2H3 cells independently of adenosine receptors or cyclic AMP: evidence for inhibition of antigen binding to IgE. J. Pharmacol. Exp. Ther. 1991, 258, 954-962.
51. Mathot, R. A. A.; Gubbensstibbe, J. M., Soudijn, W.; Jacobson, K. A.; IJzerman, A. P.; Danhof, M. Quantification of the in vivo potency of the adenosine A2 receptor antagonist 8-(3-chlorostyryDcaffeine. J. Pharmacol. Exp. Ther. 1995, 275, 245-253.
52. 3H]phenylxanthine. Proc. Natl.Acad. Sci. U.S-A. 1980, 77, 5547-5551.
53. 50) of enzyme reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
54. 6-phenylisopropyladenosine. NaunynSchmiedeberg's Arch. Pharmacol. 1980, 373, 179-187.
55. 3H]NECA in rat striatal membranes. Mol. Pharmacol. 1986, 29, 331-346.
56. Jacobson, K. A.; Shi, D.; Gallo-Rodriguez, C.; Manning, M., Jr., Müller, C. E.; Daly, J. W.; Neumayer, J. L.; Kiriasis, L.; Pfleiderer, W. Effect of trifluoromethyl- and other substituents on activity of xanthines at adenosine receptors. J. Med. Chem. 1993, 36, 2639-2644.
57. Daly, J. W.; Padgett, W.; Shamim, M. T.; Butts-Lamb, P.; Waters, J. 1,3-Dialkyl-8-(p-sulfophenyl)xanthines: potent water-soluble antagonists for Al- and A2-adensosine receptors. J. Med. Chem. 1985, 28, 487-492.